New screening method may detect twice as many cases of ovarian cancer

the ONA take:

According to a new study published in the Journal of Clinical Oncology, researchers from University College London have developed a new screening tool that can detect twice as many women with ovarian cancer as standard approaches.

Specifically, the study showed that the new method, which detects changes in CA125 levels, could detect cancer in 86% of women with invasive epithelial ovarian cancer.

CA125 is a protein biomarker in the blood of women that has been linked to ovarian cancer. A statistical test then predicts the woman's risk of having ovarian cancer.

"CA125 as a biological marker for ovarian cancer has been called into question. Our findings indicate that this can be an accurate and sensitive screening tool, when used in the context of a woman's pattern of CA125 over time," said Professor Ian Jacobs, chief investigator of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), an co-inventor of the statistical approach.

"What's normal for one woman may not be so for another. It is the change in levels of this protein that's important. My hope is that when the results of UKCTOCS are available this approach will prove capable of detecting ovarian cancer early enough to save lives."

The study evaluated 46,237 women who were screened annually for ovarian cancer over a 14-year period.

New screening method may detect twice as many cases of ovarian cancer
A new screening tool can detect twice as many women with ovarian cancer as standard approaches.
A new screening method can detect twice as many women with ovarian cancer as conventional strategies, according to the latest results from the largest trial of its kind led by UCL.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs